替格瑞洛联合硝酸甘油治疗急性心肌梗死的临床效果观察  

Clinical observation of ticagrelor combined with nitroglycerin in the treatment of acute myocardial infarction

作　　者：许钰琳 叶丹[1] 韩磊[1] XU Yu-lin;YE Dan;HAN Lei(Beijing Aerospace General Hospital,Beijing 100076,China)

机构地区：[1]北京航天总医院,100076

出　　处：《中国现代药物应用》2022年第20期1-5,共5页Chinese Journal of Modern Drug Application

摘　　要：目的分析替格瑞洛联合硝酸甘油治疗急性心肌梗死的临床效果。方法106例急性心肌梗死患者,按照治疗方式的差异性分为单一用药组和联合用药组,每组53例。单一用药组患者使用硝酸甘油氯化钠注射液治疗,联合用药组患者在单一用药组基础上使用替格瑞洛治疗。比较两组患者临床疗效、不良反应发生情况以及心功能指标[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]、生活质量、心肌梗死面积、QRS评分、血清学指标[血管内皮细胞蛋白C受体(EPCR)、C反应蛋白(CRP)、白细胞介素-8(IL-8)]。结果联合用药组治疗总有效率98.11%高于单一用药组的83.02%,不良反应发生率5.66%低于单一用药组的22.64%,差异具有统计学意义(P<0.05)。干预后,联合用药组LVEF(55.29±5.07)%高于单一用药组的(47.52±4.15)%,LVEDD(52.15±2.14)mm、LVESD(40.25±3.25)mm均小于单一用药组的(59.36±2.28)、(46.26±3.11)mm,差异均具有统计学意义(P<0.05)。联合用药组总体健康、认知能力、情感职能、活力情况、精神健康、躯体疼痛、社会功能、生理职能评分分别为(80.25±5.25)、(83.26±5.28)、(82.25±4.15)、(83.26±2.58)、(85.25±2.64)、(86.39±2.58)、(89.33±2.57)、(90.36±2.58)分,均高于单一用药组的(70.44±5.17)、(64.15±5.16)、(71.28±3.28)、(68.26±3.55)、(63.29±5.29)、(66.39±4.17)、(69.63±4.18)、(66.39±2.39)分,差异均具有统计学意义(P<0.05)。干预后,联合用药组患者QRS评分(4.34±0.63)分、心肌梗死面积(12.66±2.58)%均低于单一用药组的(5.71±0.88)分、(17.63±3.25)%,差异均具有统计学意义(P<0.05)。干预后,联合用药组患者血清IL-8(36.28±11.27)pg/ml、CRP(3.69±0.58)mg/L、EPCR(5.71±1.82)pg/ml均低于单一用药组的(56.26±14.27)pg/ml、(5.69±1.27)mg/L、(8.24±2.67)pg/ml,差异均具有统计学意义(P<0.05)。结论针对急性心肌梗死患者,应用替格瑞洛联合硝酸甘油治疗效�Objective To analyze the clinical effect of ticagrelor combined with nitroglycerin in the treatment of acute myocardial infarction.Methods A total of 106 patients with acute myocardial infarction were divided into single-drug group and combination-drug group according to the differences in treatment methods,with 53 cases in each group.Patients in the single-drug group were treated with nitroglycerin and sodium chloride injection,while patients in the combination-drug group were treated with ticagrelor on the basis of the singledrug group.Both groups were compared in terms of clinical efficacy,occurrence of adverse reactions,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],quality of life,infarct size,QRS score,serological indicators[vascular endothelial protein C receptor(EPCR),C-reactive protein(CRP),interleukin-8(IL-8)].Results The total effective rate 98.11%of the combination-drug group was higher than 83.02%of the single-drug group,and the incidence of adverse reactions 5.66%was lower than(22.64%)of the single-drug group,and the differences were all statistically significant(P<0.05).After intervention,the LVEF(55.29±5.07)%of the combination-drug group was higher than(47.52±4.15)%of the single-drug group;the LVEDD(52.15±2.14)mm and LVESD(40.25±3.25)mm of the combination-drug group were less than(59.36±2.28)and(46.26±3.11)mm of the single-drug group;the differences were all statistically significant(P<0.05).The scores of overall health,cognitive ability,emotional function,vitality,mental health,physical pain,social function,and physiological function in the combination-drug group were(80.25±5.25),(83.26±5.28),(82.25±4.15),(83.26±2.58),(85.25±2.64),(86.39±2.58),(89.33±2.57),and(90.36±2.58)points,which were higher than(70.44±5.17),(64.15±5.16),(71.28±3.28),(68.26±3.55),(63.29±5.29),(66.39±4.17),(69.63±4.18),and(66.39±2.39)points in the single-drug group,and the differences were a

关 键 词：替格瑞洛 硝酸甘油 急性心肌梗死 效果 分析 

分 类 号：R542.22[医药卫生—心血管疾病]